Drug Profile

Nefopam - MAXONA Pharmaceuticals

Alternative Names: MAX-001

Latest Information Update: 02 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MAXONA Pharmaceuticals
Class Analgesics; Antifibrotics; Non-opioid analgesics; Small molecules
Mechanism of Action Adrenergic receptor agonists; Beta catenin inhibitors; Muscarinic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Acute pain; Pain

Most Recent Events

18 Mar 2025 Efficacy and adverse event data from phase I trial in Pain released by MAXONA Pharmaceuticals
25 Feb 2025 MAXONA Pharmaceuticals has patent protection for MAX 001 in USA
19 Feb 2025 MAXONA Pharmaceuticals plans to file NDA for Acute pain in 1H of 2027 (MAXONA Pharmaceuticals pipeline; February 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com